CRISPR-Cas9 technology is a relatively recently developed tool for easy and efficient targeting of DNA. However, its efficiency for the repair of a mutated sequence is low. Moreover, most CRISPR-based gene correction approaches require the use of an exogenous template. Here, we investigated whether we could use the CRISPR-Cas9 system and the autologous repair machinery to correct human recessive genetic disorders having two different mutations in two alleles (compound heterozygotes). We reasoned that by targeting an intronic sequence located between the two mutations, we could generate at least one normal allele via the repair of induced double-strand breaks through either gene conversion or mitotic crossover. In particular, using a simple hypoxanthine-guanine phosphoribosyltransferase (Hprt)-based system, we show we can form a normal and functional Hprt gene. Thus, we give proof of principle that homology-directed recombination can be exploited in compound heterozygote cells to correct a genetic defect without exogenous templates.
Get full access to this article
View all access options for this article.
References
1.
JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337:816–821. DOI: 10.1126/science.1225829.
2.
CongL, RanFA, CoxD, et al.Multiplex genome engineering using CRISPR/Cas systems. Science, 2013; 339:819–823. DOI: 10.1126/science.1231143.
3.
MaliP, YangL, EsveltKM, et al.RNA-guided human genome engineering via Cas9. Science, 2013; 339:823–826. DOI: 10.1126/science.1232033.
4.
WitzanyG. The agents of natural genome editing. J Mol Cell Biol, 2011; 3:181–189. DOI: 10.1093/jmcb/mjr005.
5.
YangL, YangJL, ByrneS, et al.CRISPR/Cas9-directed genome editing of cultured cells. Curr Protoc Mol Biol, 2014; 107:3–1.1.1–17. DOI: 10.1002/0471142727.mb3101s107.
6.
ZhangJP, LiXL, LiGH, et al.Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome Biol. 2017; 18:3–5. DOI: 10.1186/s13059-017-1164-8.
7.
ChariR, MaliP, MoosburnerM, ChurchGM. Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nat Methods, 2015; 12:823–826. DOI: 10.1038/nmeth.3473.
8.
MaH, Marti-GutierrezN, ParkSW, et al.Correction of a pathogenic gene mutation in human embryos. Nature, 2017; 548:413–419. DOI: 10.1038/nature23305.
9.
EgliD, ZuccaroM, KosickiM, et al.Inter-homologue repair in fertilized human eggs?. bioRxiv, 2017; 181255. DOI: https://doi.org/10.1101/181255.
10.
WuY, LiangD, WangY, et al.Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell, 2013; 13:659–662. DOI: 10.1016/j.stem.2013.10.016.
11.
KaneMS, DavidsM, AdamsC, et al.Mitotic intragenic recombination: a mechanism of survival for several congenital disorders of glycosylation. Am J Hum Genet, 2016; 98:339–346. DOI: 10.1016/j.ajhg.2015.12.007.
12.
ChoateKA, LuY, ZhouJ, et al.Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science, 2010; 330:94–97. DOI: 10.1126/science.1192280.
13.
ChoateKA, LuY, ZhouJ, et al.Frequent somatic reversion of KRT1 mutations in ichthyosis with confetti. J Clin Invest, 2015; 125:1703–1707. DOI: 10.1172/JCI64415.
14.
BothmerA, PhadkeT, BarreraLA, et al.Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus. Nat Commun, 2017; 8:1390–5. DOI: 10.1038/ncomms13905.
15.
RouetP, SmihF, JasinM. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci U S A, 1994; 91:6064–6068.
UrnovFD. Genome editing B.C. (before CRISPR): lasting lessons from the “Old Testament.”. Crispr J, 2018; 1:34–46. DOI: 10.1089/crispr.2018.29007.fyu.
18.
ChenJM, CooperDN, ChuzhanovaN, et al.Gene conversion: mechanisms, evolution and human disease. Nat Rev Genet, 2007; 8:762–775.
19.
PaulisM, CastelliA, LizierM, et al.A pre-screening FISH-based method to detect CRISPR/Cas9 off-targets in mouse embryonic stem cells. Sci Rep, 2015; 5:1232–7. DOI: 10.1038/srep12327.
20.
SilvermanLJ, KelleyWN, PalellaTD. Genetic analysis of human hypoxanthine-guanine phosphoribosyltransferase deficiency. Enzyme, 1987; 38:36–44.
21.
PaulisM, CastelliA, SusaniL, et al.Chromosome transplantation as a novel approach for correcting complex genomic disorders. Oncotarget, 2015; 6:35218–35230. DOI: 10.18632/oncotarget.6143.
22.
BranzeiD, FoianiM. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol, 2008; 9:297–308. DOI: 10.1038/nrm2351.
23.
RobertsonEJ, EvansMJ, KaufmanMH. X-chromosome instability in pluripotential stem cell lines derived from parthenogenetic embryos. J Embryol Exp Morphol, 1983; 74:297–309.
24.
RastanS, RobertsonEJ. X-chromosome deletions in embryo-derived (EK) cell lines associated with lack of X-chromosome inactivation. J Embryol Exp Morphol, 1985; 90:379–388.
25.
ChoiJ, ClementK, HuebnerAJ, et al.DUSP9 modulates DNA hypomethylation in female mouse pluripotent stem cells. Cell Stem Cell, 2017; 20:706–719.
26.
YagiM, KishigamiS, TanakaA, et al.Derivation of ground-state female ES cells maintaining gamete-derived DNA methylation. Nature, 2017; 548:224–227.
27.
PasqueV, KarnikR, ChronisC, et al.X chromosome dosage influences DNA methylation dynamics during reprogramming to mouse iPSCs. Stem Cell Reports, 2018; 10:1537–1550. DOI: 10.1016/j.stemcr.2018.03.019.
28.
PasmooijAM, JonkmanMF, UittoJ. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy. Discov Med, 2012; 14:167–179.
29.
AiutiA, SlavinS, AkerM, et al.Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 2002; 296:2410–2413.
30.
AiutiA, BiascoL, ScaramuzzaS, et al.Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott–Aldrich syndrome. Science, 2013; 341:123315–1. DOI: 10.1126/science.1233151.
31.
OttMG, SchmidtM, SchwarzwaelderK, et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 2006; 1:401–409.
32.
Cavazzana-CalvoM, Hacein-BeyS, de Saint BasileG, et al.Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 2000; 288:669–672.
GasparHB, CoorayS, GilmourKC, et al.Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med, 2011; 97:97ra8–0. DOI: 10.1126/scitranslmed.3002716.
35.
Cavazzana-CalvoM, FischerA. Gene therapy for severe combined immunodeficiency: are we there yet?. J Clin Invest, 2007; 117:1456–1465.
36.
Robert-RichardE, Moreau-GaudryF, LalanneM, et al.Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. Am J Hum Genet, 2008; 82:113–124. DOI: 10.1016/j.ajhg.2007.09.007.
37.
GrossM, HanenbergH, LobitzS, et al.Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res, 2002; 98:126–135.
38.
KvittingenEA, RootweltH, BergerR, et al.Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest, 1994; 94:1657–1661.
39.
GrompeM. Fah knockout animals as models for therapeutic liver repopulation. Adv Exp Med Biol, 2017; 959:215–230.
40.
JonkmanMF, SchefferH, StulpR, et al.Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell, 1997; 88:543–551.
41.
KiritsiD, HeY, PasmooijAM, et al.Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination. J Clin Invest, 2012; 122:1742–1746. DOI: 10.1172/JCI61976.
42.
PasmooijAM, NijenhuisM, BranderR, et al.Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations. J Invest Dermatol, 2012; 132:1374–1383. DOI: 10.1038/jid.2011.477.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
